Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Notes underwriting agrmnt
AXIM BIOTECHNOLOGIES, INC. (AXIM) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/02/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Equity Purchase Agreement, by and between the Company and Investor"
05/25/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Consulting Agreement effective May 23, 2023, by and between the Company and Accalle, LLC a limited liability Company solely owned by Mr. Kurt Phinney"
01/27/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "TL-66 Convertible Notes Modification and Default Waiver Agreement",
"Executive Settlement Agreement dated January 23, 2023, and $250,000 convertible Executive Note attached thereto",
"MMI Convertible Note Modification and Default Waiver Agreement"
09/19/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "September 15, 2022, License and Distribution Agreement by and between AXIM Biotechnologies, Inc. and Verséa Ophthalmics, LLC [Portions have been omitted]",
"About AXIM® Biotechnologies Founded in 2014, AXIM® Biotechnologies, Inc. is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease. For more information, please visit www.AXIMBiotech.com . About Verséa Holdings, Inc. Verséa Holdings, Inc. headquartered in Tampa, FL, is a U.S. healthcare company founded by experienced business executives and prominent scientific medical experts with a combined 350+ years of experience, all committed to transforming scientific discoveries into applicable healthcare & wellness solutions that are critical to improving patients’ lives. ..."
08/29/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "Securities Purchase Agreement",
"Stock Purchase Agreement"
03/09/2022 8-K Quarterly results
02/16/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "Form of 1.5% Short Term Promissory Notes",
"Form of 3% Short Term Convertible Notes",
"6% Convertible Redeemable Note dated September 29, 2021, made by and between AXIM Biotechnologies, Inc. and GS Capital Partners, LLC, as amended"
01/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/03/2021 8-K Quarterly results
05/14/2021 8-K Quarterly results
07/23/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
05/12/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "AXIM® Biotechnologies Issues Update Letter to Shareholders SAN DIEGO, May 13, 2020 — AXIM ® Biotechnologies, Inc. , an international healthcare solutions company targeting oncological and cannabinoid research, announced today that it has issued a letter to its shareholders providing commentary on the Company’s recent announcements and upcoming plans. Highlights of the letter include:  Steps to clean up the Company’s balance sheet, including retiring $2.61 million in debt, the repurchase of 100% of the outstanding shares of Series B Preferred Stock held by the previous management team and the repurchase and assignment back to treasury of 18,570,356 shares of the Company's common stock.  AXIM amended a prior $4,000,000 Convertible Promissory Note that extends the maturity dat..."
05/12/2020 8-K Quarterly results
03/27/2020 8-K Other Events
01/08/2020 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these forward-looking statements"
07/09/2019 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AXIM BIOTECHNOLOGIES SIGNS LICENSING AGREEMENT WITH LEADING GUM DISTRIBUTOR TO EXPAND NUTRACEUTICAL DIVISION NEW YORK – July 9, 2019 – AXIM® Biotechnologies, Inc. , a world leader in cannabinoid research and product development, today announced that the Company has signed a multi-term agreement with KISS Industries, LLC , a gum developer based in Colorado. KISS Industries is a well-respected developer of consumer products such as CONFADENT Sugar-Free Chewing Gum. The agreement grants KISS Industries a non-exclusive license to formulate and sell products that fall within AXIM’s patent on chewing gum containing cannabinoids and grants AXIM the ability to acquire 10 percent of KISS Industries. “KISS Industries is a known leader in chewing gum formulation, producing its popular gum products to..."
04/23/2019 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AXIM Biotechnologies, Inc. Nutraceutical Division Receives Purchase Order for 50,000 Boxes of the Company’s Proprietary CBD-Based Chewing Gum"
04/04/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AXIM Biotechnologies, Inc. Appoints Mauricio Javier Gatto-Bellora to Company’s Board of Directors"
02/26/2019 8-K Quarterly results
01/15/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CORPORATE SLIDE PRESENTATION"
01/08/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/07/2018 8-K Entered into an underwriting agreement for the issuance and sale of notes
Docs: "SECURITIES PURCHASE AGREEMENT",
"CONVERTIBLE PROMISSORY NOTE",
"DEBT EXCHANGE AGREEMENT"
09/13/2018 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these forward-looking statements"
08/27/2018 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these forward-looking statements"
05/11/2018 8-K Entry into a Material Definitive Agreement
04/18/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "STOCK PURCHASE AGREEMENT",
"EXHIBIT 5.1 OPINION OF PROCOPIO, CORY, HARGREAVES & SAVITCH"
04/05/2018 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these forward-looking statements"
06/23/2017 8-K/A Quarterly results
06/16/2017 8-K Form 8-K - Current report
05/16/2017 8-K Form 8-K - Current report
05/15/2017 8-K Form 8-K - Current report
03/28/2017 8-K Form 8-K - Current report
03/22/2017 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy